Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Colony-Stimulating Factor-1 Antibody Lacnotuzumab in a Phase 1 Healthy Volunteer Study and Mechanistic Investigation of Safety Outcomes.

Pognan F, Couttet P, Demin I, Jaitner B, Pang Y, Roubenoff R, Sutter E, Timsit Y, Valentin MA, Vogel B, Woerly G, Wolf A, Schramm U.

J Pharmacol Exp Ther. 2019 Jun;369(3):428-442. doi: 10.1124/jpet.118.254128. Epub 2019 Mar 20.

PMID:
30894455
2.

Implementation of highly sophisticated flow cytometry assays in multicenter clinical studies: considerations and guidance.

Sommer U, Morales J, Groenewegen A, Müller A, Naab J, Woerly G, Kamphausen E, Marsot H, Bennett P, Kakkanaiah V, Vitaliti A.

Bioanalysis. 2015;7(10):1299-311. doi: 10.4155/bio.15.61. Review.

PMID:
26045007
3.

A functional gammadeltaTCR/CD3 complex distinct from gammadeltaT cells is expressed by human eosinophils.

Legrand F, Driss V, Woerly G, Loiseau S, Hermann E, Fournié JJ, Héliot L, Mattot V, Soncin F, Gougeon ML, Dombrowicz D, Capron M.

PLoS One. 2009 Jun 17;4(6):e5926. doi: 10.1371/journal.pone.0005926.

4.

TLR2-dependent eosinophil interactions with mycobacteria: role of alpha-defensins.

Driss V, Legrand F, Hermann E, Loiseau S, Guerardel Y, Kremer L, Adam E, Woerly G, Dombrowicz D, Capron M.

Blood. 2009 Apr 2;113(14):3235-44. doi: 10.1182/blood-2008-07-166595. Epub 2008 Oct 31.

5.

Innate immune function of eosinophils: from antiparasite to antitumor cells.

Legrand F, Woerly G, Driss V, Capron M.

Methods Mol Biol. 2008;415:215-40. doi: 10.1007/978-1-59745-570-1_13.

PMID:
18370157
6.

Acute antiinflammatory properties of statins involve peroxisome proliferator-activated receptor-alpha via inhibition of the protein kinase C signaling pathway.

Paumelle R, Blanquart C, Briand O, Barbier O, Duhem C, Woerly G, Percevault F, Fruchart JC, Dombrowicz D, Glineur C, Staels B.

Circ Res. 2006 Feb 17;98(3):361-9. Epub 2006 Jan 5.

PMID:
16397146
7.

Heterogeneity of expression of IgA receptors by human, mouse, and rat eosinophils.

Decot V, Woerly G, Loyens M, Loiseau S, Quatannens B, Capron M, Dombrowicz D.

J Immunol. 2005 Jan 15;174(2):628-35.

8.

CD28 and secretory immunoglobulin A-dependent activation of eosinophils: inhibition of mediator release by the anti-allergic drug, suplatast tosilate.

Woerly G, Decot V, Loiseau S, Loyens M, Chihara J, Ono N, Capron M.

Clin Exp Allergy. 2004 Sep;34(9):1379-87.

PMID:
15347370
9.

Peroxisome proliferator-activated receptors alpha and gamma down-regulate allergic inflammation and eosinophil activation.

Woerly G, Honda K, Loyens M, Papin JP, Auwerx J, Staels B, Capron M, Dombrowicz D.

J Exp Med. 2003 Aug 4;198(3):411-21.

10.

Inhibitory effects of ketotifen on eotaxin-dependent activation of eosinophils: consequences for allergic eye diseases.

Woerly G, Loiseau S, Loyens M, Schoch C, Capron M.

Allergy. 2003 May;58(5):397-406.

PMID:
12752326
11.

Human eosinophils express and release IL-13 following CD28-dependent activation.

Woerly G, Lacy P, Younes AB, Roger N, Loiseau S, Moqbel R, Capron M.

J Leukoc Biol. 2002 Oct;72(4):769-79.

PMID:
12377947
12.
13.

Invited lecture: role of membrane receptors in the release of T helper 1 and 2 cytokines by eosinophils.

Capron M, Woerly G, Kayaba H, Loiseau S, Roger N, Dombrowicz D.

Int Arch Allergy Immunol. 2001 Jan-Mar;124(1-3):223-6. No abstract available.

PMID:
11306976
14.

IL-4 production by human polymorphonuclear neutrophils.

Brandt E, Woerly G, Younes AB, Loiseau S, Capron M.

J Leukoc Biol. 2000 Jul;68(1):125-30.

PMID:
10914499
15.

IgE receptors on human eosinophils.

Dombrowicz D, Woerly G, Capron M.

Chem Immunol. 2000;76:63-76. Review. No abstract available.

PMID:
10761305
16.
17.

Expression of Th1 and Th2 immunoregulatory cytokines by human eosinophils.

Woerly G, Roger N, Loiseau S, Capron M.

Int Arch Allergy Immunol. 1999 Feb-Apr;118(2-4):95-7. Review.

PMID:
10224349
18.

Selectin and Lewis(x) are required as co-receptors in antibody-dependent cell-mediated cytotoxicity of human eosinophils to Schistosoma mansoni schistosomula.

Nutten S, Papin JP, Woerly G, Dunne DW, MacGregor J, Trottein F, Capron M.

Eur J Immunol. 1999 Mar;29(3):799-808.

19.
20.

Differentiation of eosinophils from cord blood cell precursors: kinetics of Fc epsilon RI and Fc epsilon RII expression.

Capron M, Morita M, Woerly G, Lengrand F, Gounni AS, Delaporte E, Capron A.

Int Arch Allergy Immunol. 1997 May-Jul;113(1-3):48-50.

PMID:
9130481
21.

Interferon-gamma enhances tumor necrosis factor-alpha production by inhibiting early phase interleukin-10 transcription.

Shakhov AN, Woerly G, Car BD, Ryffel B.

Eur Cytokine Netw. 1996 Dec;7(4):741-50.

PMID:
9010676
22.
23.

Effect of rapamycin on the expression of the IL-2 receptor (CD25).

Woerly G, Brooks N, Ryffel B.

Clin Exp Immunol. 1996 Feb;103(2):322-7.

24.

Multiple immune abnormalities in tumor necrosis factor and lymphotoxin-alpha double-deficient mice.

Eugster HP, Muller M, Karrer U, Car BD, Schnyder B, Eng VM, Woerly G, Le Hir M, di Padova F, Aguet M, Zinkernagel R, Bluethmann H, Ryffel B.

Int Immunol. 1996 Jan;8(1):23-36.

PMID:
8671586
25.

Role of interferon-gamma in interleukin 12-induced pathology in mice.

Car BD, Eng VM, Schnyder B, LeHir M, Shakhov AN, Woerly G, Huang S, Aguet M, Anderson TD, Ryffel B.

Am J Pathol. 1995 Dec;147(6):1693-707.

26.

In situ detection of cyclosporin A: evidence for nuclear localization of cyclosporine and cyclophilins.

Le Hir M, Su Q, Weber L, Woerly G, Granelli-Piperno A, Ryffel B.

Lab Invest. 1995 Nov;73(5):727-33.

PMID:
7474947
27.
28.
29.

Long-term interleukin-6 administration stimulates sustained thrombopoiesis and acute-phase protein synthesis in a small primate--the marmoset.

Ryffel B, Car BD, Woerly G, Weber M, DiPadova F, Kammüller M, Klug S, Neubert R, Neubert D.

Blood. 1994 Apr 15;83(8):2093-102.

30.

Binding of active cyclosporins to cyclophilin A and B, complex formation with calcineurin A.

Ryffel B, Woerly G, Murray M, Eugster HP, Car B.

Biochem Biophys Res Commun. 1993 Aug 16;194(3):1074-83.

PMID:
8394698
31.

Pathology induced by interleukin-6.

Ryffel B, Mihatsch MJ, Woerly G.

Int Rev Exp Pathol. 1993;34 Pt A:79-89.

PMID:
8454418
32.
33.

Covalent binding of cyclosporine inhibits irreversibly T-lymphocyte activation.

Ryffel B, Woerly G, Quesniaux VF, Husi H, Foxwell BM.

Biochem Pharmacol. 1992 Mar 3;43(5):953-60.

PMID:
1554393
34.

Identification of several cyclosporine binding proteins in lymphoid and non-lymphoid cells in vivo.

Foxwell BM, Woerly G, Husi H, Mackie A, Quesniaux VF, Hiestand PC, Wenger RM, Ryffel B.

Biochim Biophys Acta. 1992 Feb 14;1138(2):115-21.

PMID:
1540657
35.

Distribution of the cyclosporine binding protein cyclophilin in human tissues.

Ryffel B, Woerly G, Greiner B, Haendler B, Mihatsch MJ, Foxwell BM.

Immunology. 1991 Mar;72(3):399-404.

36.

[Discovery of novel immunosuppressants in vitro]

Ryffel B, Woerly G, Hofmann G, Arnold J, Greiner B, Foxwell BM.

ALTEX. 1991;8(2):31-39.

PMID:
11178561
37.

Identification of the multidrug resistance-related membrane glycoprotein as an acceptor for cyclosporine.

Ryffel B, Woerly G, Rodriguez C, Foxwell BM.

J Recept Res. 1991;11(1-4):675-86.

PMID:
1679456
38.

Inhibition of interleukin 4 receptor expression on human lymphoid cells by cyclosporin.

Foxwell BM, Woerly G, Ryffel B.

Eur J Immunol. 1990 May;20(5):1185-8.

PMID:
2141571
39.
40.
41.

Cyclosporine--relationship of side effects to mode of action.

Ryffel B, Foxwell BM, Gee A, Greiner B, Woerly G, Mihatsch MJ.

Transplantation. 1988 Aug;46(2 Suppl):90S-96S.

PMID:
3043800

Supplemental Content

Loading ...
Support Center